Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases

@article{Sartor2016ReviewAT,
  title={Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases},
  author={R. Balfour Sartor},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2016},
  volume={43}
}
  • R. Sartor
  • Published 2016
  • Medicine
  • Alimentary Pharmacology & Therapeutics
Gut microbiota dysbiosis contributes to the pathogenesis of inflammatory bowel diseases (IBD). Although the microbiota's role in IBD pathogenesis, specifically Crohn's disease (CD), provides a rationale for antibiotic treatment, antibiotic use in CD remains controversial. Rifaximin, traditionally identified as a nonsystemic bactericidal antibiotic, may be therapeutically beneficial for inducing CD remission. 
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
TLDR
The current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease is reviewed, with a special focus on the gut microbiota composition associated with these disorders. Expand
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease
TLDR
This narrative review explores the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expand
Antibiotics in inflammatory bowel diseases: do we know what we're doing?
  • O. Ledder
  • Medicine
  • Translational pediatrics
  • 2019
TLDR
An overview of the evidence implicating bacteria in the pathogenesis of gut inflammation in IBD is provided and a potential role of antibiotics in clinical practice is suggested based on available evidence and clinical experience. Expand
Rifaximin for the treatment of Crohn’s disease
TLDR
Rifaximin, a non-absorbable wide spectrum antibiotic holds promise as a treatment option in patients who have adverse reaction or contraindications to immunosuppressive and biologic therapies. Expand
Antibiotics in IBD: Still a Role in the Biological Era?
TLDR
Although antibiotics may be underused in the treatment of IBD, their integration into clinical practice must be approached judiciously and individually. Expand
The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation
TLDR
By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner. Expand
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
  • J. Kane, A. Ford
  • Medicine
  • Expert review of gastroenterology & hepatology
  • 2016
TLDR
The pharmacology of rifaximin, the evidence for its use in IBS, and the safety and tolerability of the drug are considered are considered. Expand
Gut Microbiome and Gastrointestinal Disorders
TLDR
The human gut harbors more than 1014 microorganisms, with bacteria being the main population, and the disruption of the healthy microbial structure has been associated with various gastrointestinal disorders including inflammatory bowel disease, celiac disease, irritable bowel syndrome and others. Expand
Inflammatory bowel diseases: the role of gut microbiota.
TLDR
The aim of this review is to summarize both the most recent acquisitions in the field of gut microbiota and its involvement in intestinal inflammation together with the available strategies for the modulation of microbiota, such as prebiotics and/or probiotics administration or fecal microbiota transplantation. Expand
Bugging inflammation: role of the gut microbiota
The advent of vaccination and improved hygiene have eliminated many of the deadly infectious pathogens in developed nations. However, the incidences of inflammatory diseases, such as inflammatoryExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 74 REFERENCES
Use of antibiotics in the treatment of Crohn's disease.
TLDR
Rifaximin, characterized by an excellent safety profile, has provided promising results in inducing remission of CD, and the use of metronidazole and ciprofloxacin is recommended in perianal disease. Expand
Antibiotics, probiotics and prebiotics in IBD.
  • C. Bernstein
  • Medicine
  • Nestle Nutrition Institute workshop series
  • 2014
TLDR
A review of the controlled trials undertaken to assess the use of antibiotics that would kill or suppress potentially injurious microbes, probiotics that would overpopulate the gut with potentially beneficial microbes or prebiotics that provide a metabolic substrate that enhances the growth of potential beneficial microbes. Expand
Rifaximin: beyond the traditional antibiotic activity
TLDR
This review updates the pharmacology and pharmacodynamics of rifaximin highlighting the different actions, beyond its antibacterial activity, such as alteration of virulence, prevention of gut mucosal adherence and bacterial translocation. Expand
Bacterial translocation: Overview of mechanisms and clinical impact
TLDR
The mechanisms of BT, a phenomenon in which live bacteria or its products cross the intestinal barrier, and its clinical impact based on the current literature are reviewed. Expand
The role of antimicrobials in Crohn’s disease
TLDR
Antimicrobials, especially metronidazole, are promising for inducing remission in patients with colonic CD and preventing recurrence in postileocolonic resection. Expand
Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath Test
TLDR
Short-term administration of rifaximin is effective in the therapy of bacterial overgrowth in patients with inactive CD of the ileum, thus suggesting that the control of luminal bacterial growth could be useful in the management of these patients. Expand
Is Rifaximin Effective in Maintaining Remission in Crohn's Disease?
TLDR
Remission previously obtained with standard treatment can be sustained in patients with moderately active CD after the administration of 800 mg of rifaximin, a beneficial effect of antibiotics in CD therapy. Expand
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
TLDR
It is demonstrated that rifaximin, while not altering the overall structure of the human colonic microbiota, increased bifidobacteria and led to variation of metabolic profiles associated with potential beneficial effects on the host. Expand
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
TLDR
Administration of 800 mg rifaximin-EIR twice daily for 12 weeks induced remission with few adverse events in patients with moderately active Crohn's disease. Expand
Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation
TLDR
Preadministration of rifaximin ameliorated the clinical hallmarks of colitis in DSS- and TNBS-treated hPXR mice as determined by body weight loss and assessment of diarrhea, rectal bleeding, colon length, and histology, suggesting that human PXR may be an effective target for the treatment of IBD. Expand
...
1
2
3
4
5
...